CSIMarket
 
Uniqure N v   (QURE)
Other Ticker:  
 
 
Price: $5.5900 $-0.16 -2.783%
Day's High: $5.98 Week Perf: -12.38 %
Day's Low: $ 5.47 30 Day Perf: 0.54 %
Volume (M): 2,183 52 Wk High: $ 22.48
Volume (M$): $ 12,200 52 Wk Avg: $11.23
Open: $5.81 52 Wk Low: $5.19



 Market Capitalization (Millions $) 267
 Shares Outstanding (Millions) 48
 Employees -
 Revenues (TTM) (Millions $) 112
 Net Income (TTM) (Millions $) -228
 Cash Flow (TTM) (Millions $) -211
 Capital Exp. (TTM) (Millions $) 10

Uniqure N V
Uniqure N.V. is a gene therapy company headquartered in the Netherlands, with a focus on developing treatments for genetic and rare diseases. The company was founded in 1999 and has since become a leading player in the gene therapy industry.

The company's pipeline includes several candidates in clinical and pre-clinical development. One of its most promising programs is AMT-061, a gene therapy for patients with hemophilia B. Uniqure N.V. also has a collaboration with CSL Behring to develop gene therapies for hemophilia A and B.

Uniqure N.V. has established partnerships with major pharmaceutical companies, including Pfizer, Bristol-Myers Squibb, and AbbVie. The company has also received funding from the European Union to support its research and development efforts.

Overall, Uniqure N.V. is working to advance gene therapy as a new approach to treating genetic and rare diseases, and its innovative therapies are expected to have a significant impact on patients' lives.


   Company Address: Paasheuvelweg 25 Amsterdam 1105
   Company Phone Number: 20-240-6000   Stock Exchange / Ticker: NASDAQ QURE
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Progress Unveiled: uniQure's Groundbreaking AMT-130 Gene Therapy and its Potential in Treating Huntington's Disease

Published Tue, Dec 19 2023 12:05 PM UTC


Amid the relentless pursuit of finding a cure for neurological disorders, uniQure??a leading gene therapy company??reveals a significant development that may blaze trails in treating Huntington?s disease. The update revolves around the Phase I/II clinical trials of their pioneering therapy, AMT-130, which could potentially transform the medical landscape for Huntington'...

Clinical Study

uniQure's AMT-191 Gene Therapy Receives FDA Clearance, Amidst Revenue Challenges

Published Wed, Nov 29 2023 12:05 PM UTC


In a recent development, uniQure, a leading gene therapy company, has announced the FDA clearance of their Investigational New Drug Application (IND) for AMT-191 gene therapy for Fabry Disease. This news is expected to pave the way for patient enrollment, set to begin in the first half of 2024.
Fabry Disease is a rare genetic disorder that affects the body's abilit...

Uniqure N V

Uniqure N V Struggles with Weakening Demand, Reports Deficit in Q3 2023

Weakening Demand Leads to Deficit for Uniqure N V in the Third Quarter of 2023
Uniqure N V, a major player in the pharmaceutical preparations sector, recently reported a deficit in the July to September 30, 2023 fiscal interval. The company's revenue took a hit, falling by -2.899% to $1.41 million during this period. Furthermore, the shortfall per share was at $-1.88, compared to $-1.02 per share in the reporting period a year ago.
This decline in revenue and increase in the company's deficit can be attributed to weakening demand in the market. Uniqure N V struggled to maintain its previous performance, which is evident from the fact that the major pharmaceutical preparations sector as a whole recorded a top-line rise of 1.86% relative to the same period a year ago in the third quarter of 2023.

Uniqure N V

Despite Massive 387.324% Revenue Surge in Q2 2023, Uniqure N.V Fails to Achieve Profitability Amidst Widened Deficit

Uniqure N V Continues to Impress with Strong Revenue Growth in Q2 2023
Uniqure N V, a leading company in the biotechnology sector, recently announced its second-quarter earnings for 2023, and the results were nothing short of impressive. The company reported a staggering 387.324% year-on-year revenue growth to $2.42 million, showcasing its robust performance even in challenging market conditions. While the deficit has extended at $-1.44 million, there are still promising indicators to consider.
In a surprising turn of events, Uniqure N V experienced a remarkable improvement in earnings per share (EPS) from $-1.63 per share in the previous reporting period. This improvement demonstrates that the company's unique business strategies and strong market positioning are starting to pay off. Furthermore, revenue took a hit, declining by -54.516% from $5.33 million, but the tremendous growth in other areas overshadows this decline.

Uniqure N V

Uniqure N V's Revenue Skyrockets in Q1 2023, But Fails to Break Even2.

Uniqure N V, a biotech company dedicated to gene therapy development, has recently announced its fiscal results for the 12 months ending in the first quarter of 2023. The company had a cumulative net loss of $-157 million, resulting in a negative return on assets (ROA) of -23.52 percent. These numbers may raise concerns for investors, as they indicate the company's financial performance is below the industry average.
Uniqure N V isn't the only company within the healthcare sector facing financial setbacks. Data shows that 367 other healthcare sector companies have a higher ROA than Uniqure N V. Despite this, the company has managed to advance its ROA ranking from 4003 to 3285 in the Mar 31, 2023 quarter - a positive sign for the company's future.






 

Uniqure N V's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com